01 Development of Selective Sodium Channel InhibitorsThe chronic pain market analysis highlights growing pharmaceutical interest in selective sodium channel inhibitors for neuropathic pain treatment. These drugs target pain-signaling pathways without directly activating opioid receptors. Pharmaceutical companies are advancing NaV1.8 inhibitors to address limitations associated with conventional analgesics. For example, Latigo Biotherapeutics is developing LTG-001 and LTG-305, two selective NaV1.8 inhibitors, to support non-opioid pain treatment.
02 Shift Toward LPA1 Receptor Antagonists for Chronic Pain TreatmentLysophosphatidic acid receptor 1 (LPA1) antagonists are being developed for chronic musculoskeletal pain. These drugs target pain-related signaling pathways and offer an alternative to conventional analgesics. Pharmaceutical companies are evaluating their effectiveness in osteoarthritis and chronic lower back pain. For example, Contineum Therapeutics reported positive Phase 1b safety and tolerability results for its LPA1 antagonist PIPE-791.
01 Supply chain disruptions are expected to have a moderate impact on the chronic pain market share due to shortages of active pharmaceutical ingredients (APIs), manufacturing delays, and rising drug production costs. The market is expected to experience a K-shaped recovery as established pharmaceutical companies maintain stable supplies through diversified manufacturing networks. Smaller manufacturers remain more exposed to raw material shortages and higher production costs. The market is projected to grow at a CAGR of 4.10%. Supply chain constraints could temporarily reduce growth to approximately 2.60% under an illustrative 1.5-percentage-point impact scenario. Improved API availability and manufacturing stability could support recovery toward 4.10%.
01 The chronic pain market forecasts increasing investment in non-opioid drug development and specialized pain therapies.
02 Key Investment and Funding Activities in Chronic Pain Market, 2025–2026CompanyValue (USD)DetailsArtelo Biosciences, Inc.USD 11 MillionIn March 2026, Artelo Biosciences closed a private placement to support corporate funding requirements, alongside its development of neuropathic pain treatments.Ambros Therapeutics, Inc.USD 125 MillionIn December 2025, Ambros Therapeutics secured Series A funding to advance Phase 3 clinical development of neridronate for complex regional pain syndrome.Latigo Biotherapeutics, Inc.USD 150 MillionIn March 2025, Latigo Biotherapeutics secured Series B financing to advance its selective NaV1.8 inhibitor programs for non-opioid pain treatment.
01 Clinical Preference for Non-Opioid Analgesics and Increasing Burden of Diabetic Neuropathy Drives MarketHealthcare providers are increasingly prioritizing non-opioid medications to reduce dependence on opioid-based chronic pain treatment. Concerns regarding addiction and overdose risks are encouraging the use of safer pharmacological alternatives. According to the U.S. Food and Drug Administration (FDA), approximately one in five U.S. adults with chronic pain receives opioid prescriptions. This treatment gap is strengthening demand for non-opioid analgesics and encouraging pharmaceutical investment in alternative pain medications.Nerve damage associated with diabetes often causes persistent pain that requires specialized pharmacological treatment. Anticonvulsants such as pregabalin and gabapentin are widely prescribed to manage neuropathic symptoms. The limited effectiveness of conventional analgesics in treating nerve pain is encouraging greater use of targeted medications, supporting chronic pain market growth.
01 Long-Term Drug Safety Concerns and Complex Clinical Trial Requirements Restrain Market ExpansionLong-term use of chronic pain medications presents significant safety concerns that restrict treatment choices. Opioids carry risks of dependence and overdose, while NSAIDs can increase gastrointestinal and cardiovascular complications. Anticonvulsants may also cause sedation, limiting treatment tolerance in certain patients. These adverse effects require regular clinical monitoring and dosage adjustments. Chronic pain drug development faces difficulties due to variable patient responses and high placebo effects in clinical trials. Pain intensity is largely assessed through patient-reported outcomes, making treatment effectiveness difficult to establish consistently. Differences in underlying pain mechanisms further complicate participant selection and clinical evaluation.
01 AI-Based Pain Biomarker Identification and Targeted Drug Delivery Technologies Offer Growth OpportunitiesArtificial intelligence is creating opportunities for pharmaceutical companies to develop personalized chronic pain medications. AI-based technologies can identify biological markers associated with pain mechanisms and individual drug responses. These insights help drug developers select suitable patients for clinical trials and improve treatment targeting. Pharmaceutical companies can use predictive models to develop more effective analgesics, reduce clinical trial failures, and expand their portfolios of targeted chronic pain therapies.The development of targeted drug delivery systems presents significant opportunities for pharmaceutical companies to address limitations in conventional chronic pain treatments. Sustained-release formulations can provide prolonged pain relief while reducing frequent medication requirements. Biodegradable drug carriers also offer potential for localized treatment with fewer systemic side effects.
October 2026 Viatris entered into a definitive agreement to acquire Pacira BioSciences for approximately USD 1.65 billion, strengthening its non-opioid pain treatment portfolio.
June 2026 Eli Lilly acquired 4E Therapeutics to advance the development of MNK inhibitors for non-opioid chronic pain treatment.
June 2026 AbbVie received European Commission approval for AQUIPTA (atogepant) for acute migraine treatment